Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that 5-HT receptor antagonists such as Solvay's cilansetron, Alizyme's renzapride, and Novartis's Zelmac/Zelnorm will account for 52% of the irritable bowel syndrome (IBS) drug market in 2013. Cilansetron and renzapride are due to launch within the next five years, and Zelmac/Zelnorm, already launched in the United States, will launch in Europe and Japan in 2006 and 2007, respectively.

However, the new Pharmacor study entitled Irritable Bowel Syndrome also finds that unless positive long-term safety data are made available, the 5-HT receptor antagonists may suffer limits on their success.

"5-HT receptor modulators will face uphill battles against patients' and physicians' fears about safety and tight restrictions on prescribing," said Ruth Brown, Ph.D., analyst at Decision Resources. "For example, Zelmac/Zelnorm's safety profile has been called into question by U.S. regulatory authorities--the FDA has required changes in the drug's label to include warnings about severe diarrhea in a small number of patients (0.04%) and a precautionary note about intestinal ischemia (despite no casual link) following postmarketing surveillance evaluations."

About Irritable Bowel Syndrome

Long dismissed as a psychosomatic disorder (or a medically inconsequential nuisance), IBS has captured the interest of researchers and drug developers in recent years. Sales of drug therapies for IBS in 2003 totaled $548 million in the seven major pharmaceutical markets Pharmacor covers (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan).

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall, Decision Resources, Inc., +1-781-296-2563,

Continued Adoption of Insulin Analogues and Introduction of New Insulin Formulations Will Significantly Expand the Type 1 Diabetes Drug Market

View Now